Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS

更新时间:2023-05-28

【摘要】Exenatide is the first approved glucagon-like peptide 1 receptor agonist subcutaneously or intramuscularly injected for the treatment of type 2 diabetes mellitus.Typical therapeutic plasma concentrations are in the low pg/mL range,therefore requiring ultra-sensitive quantification.To enable the accurate evaluation of pharmacokinetic studies,we established a UPLC-MS/MS assay with a lower limit of quantification(LLOQ) of 5 pg/mL(1.2 pM) using 200 μL of plasma,validated acco rding to FDA’s and EMA’s pertinent guidelines.Exenatide was isolated from plasma with solid phase extraction utilizing anionexchange sorbent.Quantification was performed with positive electrospray ionization tandem mass spectrometry in the selected reaction monitoring mode.The calibrated concentration range of 5-10,000 pg/mL was linear showing co rrelation coefficients>0.99.Interday and intraday accuracy ranged from 97.5% to 105.4% with corre sponding precision of <10.9%.Accuracy at the LLOQ ranged from 93.0% to 102.5% with corresponding precision of <15.9%.Because of the validity of a 10-fold dilution QC(accuracy 111.2%),the assay is suitable for exenatide quantification up to 100,000 pg/mL.The ultra-sensitive assay’s applicability was demonstrated by the quantification of exenatide plasma concentrations and pharmacokinetics after intravenous and nasal administration to beagle dogs.

【关键词】

阅读全文